250 related articles for article (PubMed ID: 12552961)
1. The rational development of capecitabine from the laboratory to the clinic.
Pentheroudakis G; Twelves C
Anticancer Res; 2002; 22(6B):3589-96. PubMed ID: 12552961
[TBL] [Abstract][Full Text] [Related]
2. Capecitabine (Xeloda): from the laboratory to the patient's home.
Pentheroudakis G; Twelves C
Clin Colorectal Cancer; 2002 May; 2(1):16-23. PubMed ID: 12453332
[TBL] [Abstract][Full Text] [Related]
3. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
Aprile G; Mazzer M; Moroso S; Puglisi F
Anticancer Drugs; 2009 Apr; 20(4):217-29. PubMed ID: 19247178
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacological and clinical properties of Xeloda (Capecitabine), a new oral active derivative of fluoropyrimidine].
Nishida M
Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):549-53. PubMed ID: 14639009
[TBL] [Abstract][Full Text] [Related]
6. Development of and clinical experience with capecitabine (Xeloda) in the treatment of solid tumours.
Sternberg CN; Reichardt P; Holland M
Eur J Oncol Nurs; 2004; 8 Suppl 1():S4-15. PubMed ID: 15341878
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine in breast cancer: current status.
Smorenburg CH; Bontenbal M; Verweij J
Clin Breast Cancer; 2001 Jan; 1(4):288-93; discussion 294. PubMed ID: 11899351
[TBL] [Abstract][Full Text] [Related]
8. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients.
Poole C; Gardiner J; Twelves C; Johnston P; Harper P; Cassidy J; Monkhouse J; Banken L; Weidekamm E; Reigner B
Cancer Chemother Pharmacol; 2002 Mar; 49(3):225-34. PubMed ID: 11935215
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine, a new oral fluoropyrimidine for the treatment of colorectal cancer.
Di Costanzo F; Sdrobolini A; Gasperoni S
Crit Rev Oncol Hematol; 2000 Aug; 35(2):101-8. PubMed ID: 10936467
[TBL] [Abstract][Full Text] [Related]
10. Rational development of capecitabine.
Venturini M
Eur J Cancer; 2002 Feb; 38 Suppl 2():3-9. PubMed ID: 11841929
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine in the treatment of colorectal cancer.
O'Neill VJ; Cassidy J
Future Oncol; 2005 Apr; 1(2):183-90. PubMed ID: 16555988
[TBL] [Abstract][Full Text] [Related]
12. [Mechanism and possible biochemical modulation of capecitabine (Xeloda), a newly generated oral fluoropyrimidine].
Saeki T; Takashima S
Gan To Kagaku Ryoho; 1999 Mar; 26(4):447-55. PubMed ID: 10097741
[TBL] [Abstract][Full Text] [Related]
13. Moving forward with capecitabine: a glimpse of the future.
Biganzoli L; Martin M; Twelves C
Oncologist; 2002; 7 Suppl 6():29-35. PubMed ID: 12454317
[TBL] [Abstract][Full Text] [Related]
14. Capecitabine: an overview of the side effects and their management.
Saif MW; Katirtzoglou NA; Syrigos KN
Anticancer Drugs; 2008 Jun; 19(5):447-64. PubMed ID: 18418212
[TBL] [Abstract][Full Text] [Related]
15. Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness.
Twelves CJ
Clin Colorectal Cancer; 2006 Nov; 6(4):278-87. PubMed ID: 17241512
[TBL] [Abstract][Full Text] [Related]
16. [Discovery and development of novel anticancer drug capecitabine].
Ishitsuka H; Shimma N; Horii I
Yakugaku Zasshi; 1999 Dec; 119(12):881-97. PubMed ID: 10630095
[TBL] [Abstract][Full Text] [Related]
17. [Capecitabine].
Yamaguchi K; Shimamura T; Tada M
Gan To Kagaku Ryoho; 2006 Jul; 33(7):891-5. PubMed ID: 16835474
[TBL] [Abstract][Full Text] [Related]
18. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
Twelves C; Boyer M; Findlay M; Cassidy J; Weitzel C; Barker C; Osterwalder B; Jamieson C; Hieke K;
Eur J Cancer; 2001 Mar; 37(5):597-604. PubMed ID: 11290435
[TBL] [Abstract][Full Text] [Related]
19. Rational design of new tumoractivated cytotoxic agents.
Verweij J
Oncology; 1999 Jul; 57 Suppl 1():9-15. PubMed ID: 10436411
[TBL] [Abstract][Full Text] [Related]
20. New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
Cunningham D; Coleman R
Cancer Treat Rev; 2001 Aug; 27(4):211-20. PubMed ID: 11545541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]